AIDX 20/20 Biolabs, Inc.

P/E --
Forward P/E --
Price/Sales 3.302
Beta -0.425
Div Yield --
Market Cap --

Company Analysis

Latest News

🟒 20/20 Biolabs is trading 5.1% up today in a minor bounce after recent weakness

20/20 Biolabs is trading 5.1% up at $0.54 in thin pre-market action, staging a modest rebound after closing at $0.51 on July 23, 2026. β€’ The move appears to...

πŸ”΄ 20/20 Biolabs is trading 5.2% down today amid broader market weakness and no clear company-specific catalyst

20/20 Biolabs is trading at $0.49, down 5.2% in after-hours sessions, extending a recent multi-day decline from its July 22 level of $0.55. β€’ The downward...

πŸ”΄ 20/20 Biolabs is trading 10.4% down

20/20 Biolabs is trading at $0.49, down 10.4% from a comparison close of $0.55 during regular trading. This is a price-action follow-up, so a separate catalyst...

AIDX Receives Nasdaq Delisting Notice and Enters 120-Day Investor Standstill Agreement

AIDX Receives Nasdaq Delisting Notice and Enters 120-Day Investor Standstill Agreement

20/20 Biolabs, Inc. (AIDX) disclosed it received a non-compliance notice from Nasdaq for failing to maintain a minimum $1.00 bid price. Concurrently, the...

πŸ”΄ 20/20 Biolabs is trading 5.1% down today amid softening small-cap risk appetite

20/20 Biolabs is trading 5.1% down at $0.50 in after-hours trading, primarily driven by a broader softening in small-cap risk appetite. β€’ The move extends a...

πŸ”΄ 20/20 Biolabs is trading 5% down today tracking weak small-cap risk tone

20/20 Biolabs is trading at $0.49 (-5.02%) as the stock tracks a broader weak small-cap risk tone with no clear company-specific catalyst in available...

πŸ”΄ 20/20 Biolabs is trading 5.1% down today in a technical pullback following a sentiment-driven rebound

20/20 Biolabs is trading 5.1% down at $0.52 as the stock undergoes a technical pullback following a short-term, sentiment-driven rebound on July 15, 2026. β€’...

πŸ”΄ 20/20 Biolabs is trading 5.2% down today after yesterday’s short-term rebound

20/20 Biolabs is trading 5.2% down at $0.52 in pre-market sessions following a short-term rebound in the previous session. β€’ The move follows a prior...

🟒 20/20 Biolabs is trading 6% up today as it extends a short-term rebound on no clear news catalyst

20/20 Biolabs is trading approximately 6% higher at $0.59 in pre-market as it extends a short-term rebound from recent weakness. β€’ The move appears to be...

🟒 20/20 Biolabs is trading 9.1% up today as it extends a rebound on no clear news catalyst

20/20 Biolabs is trading at $0.60 (up 9.1%) in pre-market action, extending a modest rebound from recent weakness despite a lack of fundamental news. β€’ The...

🟒 20/20 Biolabs is trading 6.2% up today, rebounding from recent weakness on no clear news catalyst

20/20 Biolabs is trading at $0.58 (6.2% up) in after-hours trading, rebounding modestly from recent weakness despite a lack of fresh news. β€’ No...

πŸ”΄ 20/20 Biolabs is trading 5.8% down today amid broader biotech sector weakness

20/20 Biolabs is trading at $0.56 (-5.76%) as it extends a pullback from its recent AI-driven rebound, largely tracking a downturn in the broader industry. β€’...

πŸ”΄ 20/20 Biolabs is trading 5.7% down today as it gives back gains from its recent AI-driven rebound

20/20 Biolabs is trading 5.7% down at $0.55 today, retracing a portion of its recent gains following industry recognition for its clinical AI tools. β€’ The...

🟒 20/20 Biolabs is trading 6.4% up today as AMIA recognition of its clinical AI tools sustains momentum

20/20 Biolabs is trading at $0.61 (6.4% up) as the company continues to see positive momentum following industry recognition of its artificial intelligence...

🟒 AIDX Rises 3.39% in Pre-Market Following AMIA Recognition for Clinical AI Advancement

β€’ AIDX is trading at $0.61 (+3.39%) in pre-market trading today, rebounding from a prior weak session. β€’ The upward movement follows news on July 7, 2026, that...

πŸ”΄ AIDX is trading 5.4% down today amid thin liquidity and micro-cap volatility

AIDX is trading 5.4% down at $0.59 today, driven by thin liquidity and a broader risk-off market tone. β€’ The move comes despite a lack of new company-specific...

πŸ”΄ AIDX is trading 5.9% down today amid thin liquidity and risk-off sentiment

AIDX is trading at $0.59, down 5.9%, following a modest multi-day rebound observed in late June and early July. β€’ There are currently no fresh...

🟒 AIDX is trading 5.9% up today after its acquisition-heavy growth plan webinar

AIDX is trading 5.9% up now at $0.65 as investors react to its July 1 investor webinar outlining an aggressive buy‑and‑build acquisition strategy and scaling...

20/20 Biolabs Pitches a Buy-and-Build Future, but Can a $6 Million Company Really Pull Off an Acquisition Spree?

20/20 Biolabs Pitches a Buy-and-Build Future, but Can a $6 Million Company Really Pull Off an Acquisition Spree?

Shares of 20/20 Biolabs (AIDX) slid 9.6% to $0.55 on July 2 as investors digested the company's inaugural investor webinar, held July 1, which laid out an...

πŸ”΄ AIDX is trading 9.6% down today as investors digest new strategy and M&A plans

AIDX is trading at $0.55 (9.6% down) as investors react to the company's recently unveiled strategic roadmap and M&A objectives. β€’ The price movement follows...